By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Pierre Fabre 

Centre d'Immunologie Pierre FABRE
5, avenue Napolean III - BP 497
St. Julien en Genevois Cedex    74164  France
Phone: 33-4-50-35-35-55 Fax: 33-4-50-35-35-90


SEARCH JOBS


Industry
Biotechnology


Collaborations

Merck & Co., Inc.  Cancer





Company News
Pierre Fabre Obtains European Commission Marketing Authorization For Hemangiol®, The First And Only Drug Approved For The Treatment Of Proliferating Infantile Hemangioma 5/5/2014 9:05:15 AM
Pierre Fabre Selects Pierre Fabre Doccompliance To Manage Quality Documents Across Entire Organization 4/28/2014 9:56:19 AM
Pierre Fabre Obtains FDA Approval To Market Hemangeo™ For The Treatment Of Infantile Hemangioma 3/18/2014 6:57:31 AM
Aurigene Discovery Technologies Limited And Pierre Fabre Announce A Licensing Agreement For A New Cancer Therapeutic In Immuno-Oncology : AUNP12, An Immune Checkpoint Modulator Targeting The PD-1 Pathway 2/12/2014 9:29:48 AM
Forest Laboratories, Inc. (FRX) and Pierre Fabre Grab FDA OK on Depression Drug 7/26/2013 6:37:56 AM
ADVENTRX Pharmaceuticals Inc. (ANX) and Pierre Fabre Announce Manufacturing Agreement for ANX-188 Drug Substance 6/12/2012 10:55:07 AM
Pierre Fabre Selects Dassault Systèmes SolidWorks Corp.' Version 6 Platform to Deploy Next-Generation PLM for Life Sciences 11/22/2011 10:01:54 AM
Sales of Dermo-Cosmetics on the Internet: Ruling by the EU Court of Justice Allows Pierre Fabre to Defend Their Right to an Individual Exemption 10/13/2011 12:11:56 PM
MediGene AG (MDGEF.PK) and Pierre Fabre Sign Agreement for the Commercialization of Veregen(R) in Mexico, Central America, Venezuela and Colombia 2/22/2011 11:05:33 AM
Forest Laboratories, Inc. (FRX) and Pierre Fabre Announce Topline Phase III Results from a Study of Levomilnacipran for the Treatment of Major Depressive Disorder; Drug Fails to Meet Statistical Significance 1/20/2011 6:34:06 AM
123
//-->